“Integrated Safety Analysis of Ritlecitinib in Adolescent Patients With Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b 3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 6, Nov. 2023, p. s294, https://doi.org/10.25251/skin.7.supp.294.